Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.
Researchers are comparing different treatments for triple-negative breast cancer (TNBC). The people in this study have TNBC that has been surgically removed.
Researchers are doing this study is to find the highest dose of a new cell therapy for people with leukemia. The people in this study have acute myelogenous leukemia (AML) that keeps growing even after treatment. They will get the new treatment with atezolizumab, an immune-boosting therapy.
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
Researchers want to find the best dose of BDTX-4933 to use in people with advanced lung cancer. The people in this study have non-small cell lung cancer that has a mutation (change or variant) in the BRAF or KRAS genes (KRAS non-G12C mutation). This mutation can cause cancer cells to grow.
This study is comparing two treatment regimens for advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma that has metastasized (spread). They have not yet had treatment for advanced disease.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.
